Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genetic Testing Solutions > NACE

NACE Non-invasive prenatal test

Non-invasive prenatal screening helps to avoid unnecessary amniocentesis

NACE Non-invasive prenatal test
  • Technical Overview
  • Documentation
  • Scientific evidence
  • I’m not a health specialist

Screens for the most common chromosomal abnormalities without risk to your child

Highest informativity rate in the market: we obtain results for 99% of the analyzed samples

POC Products of Conception

Available from week 10 of pregnancy

Reduces unnecessary amniocentesis

Interested in learning more?

Request information
Or Email us at supportspain@igenomix.com
Overview
  • NACE
  • Benefits
  • Indications

What is NACE?

  • NACE is a non-invasive prenatal screening test for the most frequent chromosomal abnormalities. The test is non-invasive, meaning that there is no risk to the fetus.
  • A simple blood draw from the mother allows free fetal DNA circulating in the maternal bloodstream to be detected via next-generation sequencing (NGS) technology and our proprietary bioinformatic analysis tool.

What options are available?

  • NACE: Detects abnormalities in chromosomes 21, 18, 13 and the most common anomalies in the sex chromosomes (X and Y).
  • NACE 24: Analyzes the full set of chromosomes at the resolution of a standard karyotype. It identifies deletions and duplications that are associated with clinically relevant genetic syndromes.
NACE Non-invasive prenatal test

What is the procedure?

NACE Non-invasive prenatal test

Why use NACE test?

  • Prevent the need for 98% of invasive tests in patients at risk for trisomy 21 (Down Syndrome).
  • Reduces the number of miscarriages caused by amniocentesis or chorionic villus sampling (CVS).
  • Can give results with fetal fraction under 4%.
  • NACE has the highest informatively rate in the market: we obtain results for 99% of the analyzed samples.
  • More reliable than 1st trimester combined screening. The false positive rates of conventional tests, including biochemical screening, mean that 1 in every 20 women who test positive for Down syndrome will actually be carrying a healthy baby.
  • Avoid a false sense of security: Of every 20 women carrying a baby with Down syndrome, 3 will test negative by biochemical screening.
  • The new NACE 24 technology allows analysis of aneuploidies (mainly trisomies) as well as deletions and duplications greater than 7Mb. This allows a more detailed investigation of high-risk pregnancies, to identify potentially clinically relevant conditions such as true fetal mosaicism, uniparental disomy and chromosomal imbalances (when the parents are carriers of balanced translocations).
NACE Non-invasive prenatal test

Who is NACE suitable for?

Several scientific studies support the use of non-invasive prenatal testing for all pregnant women.

  • An abnormal result in their first-trimester screen.
  • A previous Down´s syndrome pregnancy
  • A suspicious ultrasound finding.

(Gregg, et al. Genet Med. 2016)

Test Limitations

  • cfDNA screening is considered a screening test and not a diagnostic test. 
  • False non-invasive prenatal screening (NIPT) results: fetoplacental mosaicism, maternal chromosomal abnormalities, vanishing twin syndrome and/or errors associated with the procedures. 
  • Low-molecular-weight heparin can interfere with the analysis. If the patient is taking heparin during pregnancy, the recommendation is to perform the blood draw before heparin administration. 
Documentation
  • Specialists’ documents

NACE Clinical Sheets

Download

NACE 24 Clinical Sheets

Download

Brochure

Download

Instructions

Download
Scientific evidence

Relevant related studies:

Milan M, Mateu E, Blesa D, Clemente-Ciscar M, Simon C. Fetal sex determination in twin pregnancies using cell free fetal DNA analysis. Prenat Diagn. 2018 Apr 23.

Gregg AR et al. Genet Med 2016; 18:1056-65.

Bianchi et al. N Engl J Med. 2014 27;270 (9):799-808.

Nicolaides KH. Prenat Diagn 2011; 31:7-15-

FAQs

Opening hours, contact details, lab address...

User manual

If you're a little lost with this technical information...

Can we help you?

I’m not a health specialist

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix

Other services

ERA

Evaluates the endometrial receptivity

More information
PGT-A Preimplantation Genetic Testing

PGT-A

Chromosomally normal
embryos selection

More information
CGT Carrier Genetic Test

CGT

Determines the risk of having a child with a genetic disease

More information

Igenomix is in the media

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information